Medical Education News

NAMEC and CME Industry Related News.


<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • 10 May 2017 3:47 PM | NAMEC Staff Jim Ranieri (Administrator)

    Date CGA Issued: May 9, 2017

    Clinical Area: Oncology Outcomes & Evidence

    Link to full CGA: Understanding Oncology Clinical Trial Outcomes and Comparative Assessment

    Due Date: June 21, 2017

    Specific Area of Interest: It is our intent to support continuing professional development programs (CME/CE) for managed care decision-makers, formulary decision-makers, other payor decision-makers, pharmacists/pharmacy directors, and medical oncologists/medical directors. Proposed programs should focus on increasing the understanding of one or more of the following topics, in order of priority:

    1.     Formulary Class Review & Considerations: Examining Current and Emerging Agents in the CDK 4/6 Inhibitor Class for the Treatment of HER2(-)/ER(+) Advanced or Metastatic Breast Cancer

    2.     The use of Patient Reported Outcomes (PROs) in Oncology Versus Other Therapeutic Areas and a Primer for Payers to the PRO-Common Terminology Criteria for Adverse Events Tool (PRO-CTCAE tool)

    3.     Application & Limitations of Evidenced-Based Methods for Indirect Treatment & Trials Comparisons: Value frameworks (ASCO Value Framework, NCCN Evidence Blocks, etc) and Real World Data for indirect treatment comparisons; and Network Meta-Analysis (NMA), Simulated Treatment Comparison (STC), Match Adjusted Treatment Comparison (MAIC), etc. for indirect trials comparisons

    4.     Challenges with Oncology Trial Design/Approvals & Endpoints in Value Assessment

    Questions regarding this CGA should be directed to derek.warnick@pfizer.com.


  • 09 May 2017 11:25 AM | NAMEC Staff Jim Ranieri (Administrator)

    Request for Proposal (RFP)
    Shared Management of Psoriatic Arthritis

    The mission of Pfizer Independent Grants for Learning & Change (IGLC) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. “Independent” means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

    Date RFP Issued: May 8, 2017

    Clinical Area: Psoriatic Arthritis

    Link to full RFP: Shared Management of Psoriatic Arthritis

    LOI Due Date: June 23, 2017

    Specific Area of Interest:   Evidence indicates that many patients with Psoriatic Arthritis (PsA) remain undiagnosed, and those who have been diagnosed are not receiving optimal care. It is our intent to support projects that focus on the coordinated management and identification of patients with psoriatic arthritis (PsA) by both rheumatology and dermatology healthcare professionals. 

    Patients with Psoriatic Arthritis experience symptoms that involve both the skin and the joints, impacting their quality of life. Given the nature of the disease, patients may seek care from both dermatologists and rheumatologists, as the disease progresses through periods of flare and remission. A collaborative approach to treatment by a combined team of rheumatology and dermatology clinicians allows for a unique blend of expertise and provides the opportunity for comprehensive care for the PsA patient.

    It is expected that projects will be evidence-based and the proposed evaluation will follow generally accepted scientific principles. During review the intended outcome of the project is given careful consideration and, if appropriate based on the project goal, projects with the maximum likelihood to directly impact patient care will be given high priority.

    Refer to complete details in the Full RFP document. Questions regarding this RFP should be directed to amanda.solis@pfizer.com.

  • 09 May 2017 10:17 AM | NAMEC Staff Jim Ranieri (Administrator)

    Pfizer and Bristol-Myers Squibb (BMS) are working together on grants in support of innovative cardiovascular therapies. The goal of these grants is to improve patient care and outcomes through therapy innovation.

    PLEASE NOTE: Responses to the RFP listed below should be made through the Bristol-Myers Squibb Grants and Giving website: 

    http://www.bms.com/responsibility/grantsandgiving/support/pages/default.aspx

    Request for Proposals (RFP)
    Eliminating Barriers to Innovate Cardiovascular Therapies
    to Improve Patient Care and Outcomes

    Date RFP Issued: May 1, 2017

    Clinical Area: Cardiovascular

    Link to full RFP:  Eliminating Barriers to Innovate Cardiovascular Therapies to Improve Patient Care and Outcomes

    Due Date: June 28, 2017

    Geographic Scope: United States​

    Specific Area of Interest: Chronic disease is the leading cause of death and disability in the United States. Accessing affordable treatments is vital for all Americans. There are many factors that may limit both patient and provider ability to access the newest and most innovative therapies including restrictive formularies, step therapy, non-medical switching, cost and cumbersome administrative processes including prior authorization and tier exception processes. The strategies employed to address these barriers may include

    ·         Gaining an understanding of barriers from each stakeholder’s point of view (HCP, Patient, administrative staff, caregivers, others)

    ·         Developing best practices that can inform advocacy organizations and medical societies, including the role each could play in the evolving access landscape

    Questions regarding this RFP should be directed to nicole.peterson@bms.com.

  • 26 Apr 2017 1:19 PM | NAMEC Staff Jim Ranieri (Administrator)


    The American Medical Association (AMA) and the Accreditation Council for Continuing Medical Education (ACCME®) are today opening a call for comment on their proposal to simplify and align their expectations for accredited continuing medical education (CME) activities that offer the AMA PRA Category 1 Credit™. Comments will be accepted through May 25, 2017, at 5 pm CDT.

    Reflective of the AMA and ACCME’s shared values, the proposal for alignment is designed to encourage innovation and flexibility in accredited CME while continuing to ensure that activities meet educational standards and are independent of commercial influence. The proposal is aimed at allowing accredited CME providers to introduce and blend new instructional practices and learning formats that are appropriate to their learners and setting, provided they abide by the seven core requirements described in the proposal. 

    The core requirements outlined in the proposal are aligned with ACCME requirements—and do not represent any new rules for accredited providers. However, the AMA has simplified and reduced its learning format requirements to provide more flexibility for CME providers. To further encourage innovation in educational design and delivery, CME providers may design and deliver an activity that uses blended or new approaches to driving meaningful learning and change. For these activities, the provider can designate credits on an hour-per-credit basis using their best reasonable estimate of the time required to complete the activity. Additional details about the “Proposed Simplification of Requirements for Accredited CME Activities Certified for AMA PRA Category 1 Credit™” can be found below this news release. 

    “We celebrate this collaborative effort with our AMA colleagues and the opportunity to advance the evolution of CME. This proposal reflects the values of our CME providers and supports their aspirations to engage in education that makes a meaningful difference in clinician practice and patient care. We want to do everything we can to encourage innovation and experimentation in CME, so that educators are free to respond nimbly to their learners’ changing needs while staying true to core principles for educational excellence and independence. We thank accredited CME providers for their participation in this process and look forward to their feedback on our proposal and to our continued work together to drive quality in postgraduate medical education and improve care for the patients and communities we all serve,” said Graham McMahon, MD, MMSc, President and CEO, ACCME.

    “Based on the feedback we received from the CME community during listening sessions, we recognize the need to better align the AMA and ACCME’s requirements for CME accreditation and reaccreditation,” said Susan Skochelak, M.D., AMA Group Vice President for Medical Education. “We believe that our proposal will support the evolution of CME to better meet the needs of educators, physicians, and the patients they serve. We want to hear from the CME community to make sure the proposal addresses their feedback. We encourage CME providers to submit their comments to the proposal so we can continue to evolve to a more streamlined system that meets their needs.”

    In addition to collaborating on the proposal, the AMA and ACCME produced a shared glossary of terms and definitions to help clarify terminology for accredited CME providers and learners. Developed both as part of their alignment efforts and in response to requests from CME providers, the AMA is also seeking feedback on the glossary during the comment period.

    Following the call for comment period, the AMA and ACCME will analyze the feedback and determine whether to make modifications to the proposal and glossary. Once finalized, the resulting new process will be integrated into the existing accreditation and reaccreditation processes.

    The alignment proposal was developed by the Bridge Committee, which was formed by the AMA and ACCME to support their collaborative realignment efforts. The committee—made up of staff and volunteers from both organizations—serves in an advisory capacity on issues related to alignment and the evolution of the two complementary systems of credit and accreditation.

    PROPOSED SIMPLIFICATION OF REQUIREMENTS FOR ACCREDITED CME ACTIVITIES CERTIFIED FOR AMA PRA CATEGORY 1 CREDITTM

    Based on feedback from the community and a comprehensive review of the AMA PRA Category 1 CreditTM requirements, the American Medical Association (AMA) Council on Medical Education and Accreditation Council for Continuing Medical Education (ACCME®) are proposing an alignment of their expectations for accredited CME activities certified for AMA PRA Category 1 Credit™. Reflective of the AMA and ACCME’s shared values, the proposal for alignment is designed to encourage innovation and flexibility, while ensuring that activities are independent and educationally appropriate. Accredited CME providers can introduce and blend new instructional practices and formats appropriate to their learners and setting, as long as they abide by the core requirements. CME providers may designate an activity format as “other” if it does not fall into one of the established format categories, without asking permission from the AMA. For these activities, providers can designate credits on an hour-per-credit basis, using their best reasonable estimate of the time required to complete the activity. 

    This proposal contains the following two elements:

    A. Core requirements for activities
    B. A limited number of format-specific requirements

    A. Core Requirements for Activities

    Please note: The core requirements are aligned with ACCME requirements and do not represent any new rules for accredited providers.

    1. The CME activity must conform to the AMA/ACCME definition of CME.
    2. The CME activity must address an educational need (knowledge, competence or performance) that underlies the professional practice gaps of that activity’s learners.
    3. The CME activity must present content appropriate in depth and scope for the intended physician learners.
    4. When appropriate to the activity and the learners, the accredited provider should communicate the identified educational purpose and/or objectives for the activity, and provide clear instructions on how to successfully complete the activity.
    5. The CME activity must utilize one or more learning methodologies appropriate to the activity’s educational purpose and/or objectives.
    6. The CME activity must provide an assessment of the learner that measures achievement of the educational purpose and/or objective of the activity.
    7. The CME activity must be planned and implemented in accordance with the ACCME Standards for Commercial Support: Standards to Ensure Independence in CME Activities.

    B. If the learning modality is an enduring material, journal-based CME, or performance improvement CME, the accredited provider must ensure the following format-specific requirements are met: 

    1. Enduring materials will provide access to appropriate bibliographic sources to allow for further study.
    2. Journal-based CME will include one or more peer-reviewed articles.
    3. Performance improvement CME will:
    • have an oversight mechanism that assures content integrity of the selected performance measures. If appropriate, these measures should be evidence-based and well-designed.
    • provide clear instruction to the physician that defines the educational process of the activity (documentation, timeline).
    • provide adequate background information so that physicians can identify and understand the performance measures that will guide their activity and the evidence behind those measures (if applicable).
    • validate the depth of physician participation by a review of submitted PI CME activity documentation.
    • consist of the following three stages:
    • Stage A: learning from current practice performance assessment. Assess current practice using the identified performance measures, either through chart reviews or some other appropriate mechanism.
    • Stage B: learning from the application of PI to patient care.  Implement the intervention(s) based on the results of the analysis, using suitable tracking tools.  Participating physicians should receive guidance on appropriate parameters for applying the intervention(s).
    • Stage C: learning from the evaluation of the PI CME effort.  Reassess and reflect on performance in practice measured after the implementation of the intervention(s), by comparing to the original assessment and using the same performance measures. Summarize any practice, process and/or outcome changes that resulted from conducting the PI CME activity.

    More Information

    • “Proposed Simplification of Requirements for Accredited CME Activities Certified for AMA PRA Category 1 Credit™ is appended to this news release.
    • Respond to the call for comment here.
    • Download the shared glossary.
    • CME providers: please contact info@accme.org for more information. 
  • 20 Apr 2017 11:29 AM | NAMEC Staff Jim Ranieri (Administrator)

    Pfizer
    Independent Grants for Learning & Change

    Call for Grant Applications (CGA)
    Advances in the Treatment of Renal Cell Carcinoma
     
    Date CGA Issued: April 19, 2017
    Clinical Area: Renal Cell Carcinoma
    Geographic Scope: United States, Europe
    Link to full CGA: Advances in the Treatment of Renal Cell Carcinoma
    Due Date: May 31, 2017
     
    Specific Area of Interest:  It is our intent to support continuing professional development programs (CME/CE) for medical oncologists, urologists, nurses, nurse practitioners, physician assistants and other healthcare professionals involved in the care and treatment of patients with RCC. Proposed programs should focus on understanding adjuvant therapy in oncology. Other topics of interest are current and future treatment sequencing with tyrosine-kinase inhibitors (TKIs) and adverse event management for patients with RCC.
     
    Questions regarding this CGA should be directed to derek.warnick@pfizer.com.

  • 18 Apr 2017 9:43 AM | NAMEC Staff Jim Ranieri (Administrator)

    The Patient-Centered Outcomes Research Institute (PCORI) plans to award $20.5 million as part of the Eugene Washington PCORI Engagement Awards program. These awards support projects that encourage active integration of patients, caregivers, clinicians, and other healthcare stakeholders as integral members of the patient-centered outcomes research/clinical effectiveness research (PCOR/CER) enterprise.

    View additional details

  • 12 Apr 2017 12:43 PM | NAMEC Staff Jim Ranieri (Administrator)

    Pfizer Independent Grants for Learning & Change
    Request for Proposals (RFP)
    Strategies to Support Increasing Exercise and
    Activity in Haemophilia Patients
     
    Date RFP Issued: April 10, 2017
    Clinical Area: Haemophilia
    Strategies to Support Increasing Exercise & Activity in Haemophilia Patients
    Letter of Intent Due Date: June 5, 2017
    Geographic Region: Europe, Japan, Australia, and New Zealand
     
    Specific Area of Interest:
    It is our intent to support projects that focus on the importance of physical activity in haemophilia patients as part of the approach to the management of haemophilia. In particular, we are keen to support projects that encourage patients to partake in appropriate physical activity, taking into account the individual patient’s bleeding history, physical status, age, interests and social requirements. The objective is to improve patients’ physical wellbeing, their pain perception, their quality of life (QoL) and their illness behavior.
     
    Multi-disciplinary collaborations, are encouraged when appropriate, but all partners must have a relevant role in the proposed project.
     
    It is expected that projects will be evidence-based (education and/or quality improvement) and the proposed research/evaluation will follow generally accepted scientific principles.
     
    Refer to complete details in the Full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jo Habron (jo.harbron@pfizer.com).

  • 22 Mar 2017 1:06 PM | NAMEC Staff Jim Ranieri (Administrator)
    The Accreditation Council for Continuing Medical Education (ACCME®) is pleased to present a new logo, tagline, and color palette that emphasize the lifelong journey of learning and celebrate the forward trajectory of the continuing medical education (CME) community. New marks are also available for CME providers to communicate their accreditation status. A video about these new endeavors is found below or you can view the ACCME's press release.



  • 22 Mar 2017 11:01 AM | NAMEC Staff Jim Ranieri (Administrator)

    Pfizer RFP: Immuno-Oncology - Pan-tumor
    LOI Due Date: May 1, 2017

    View complete RFP

  • 16 Mar 2017 9:22 AM | NAMEC Staff Jim Ranieri (Administrator)

    BMS has issued 3 RFPs for Independent Medical Education grants due April 6, 2017 titled:

    • Immunotherapy treatment in the management of various cancers
    • Immunotherapy treatment in the management of various cancers in a managed care setting
    • Current and future role of biomarkers in predicting pan-tumor response to immunotherapy in cancer/Biomarkers role in guiding cancer treatment

    For more information on these grants, click here.

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 

Find a medical education company 

NAMEC
3416 Primm Lane
Birmingham, AL 35216
(205) 824-7612
 

Staffed by Prime Management Services, an Association Management Company

© 2016 NAMEC. All rights reserved.

Powered by Wild Apricot Membership Software